Merck Millipore’s collaboration with celares GmbH launches pegylation services for protein-based therapeutics.
Merck Millipore, the life science business of Merck, announced a collaboration with celares GmbH to provide pegylation services to customers developing protein-based therapeutics and biosimilars. The service includes feasibility studies, process and analytical development, and scale-up from milligram to gram quantities for pilot and subsequent commercial scale.
The services will leverage EMD Millipore’s functionalized PEG products of different molecular weight and activation chemistry, buffers, solvents and excipients, and unit operations employed during the pegylation process and subsequent purification including tangential and normal flow filtration and chromatography.
Source: Merck Millipore
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.